公开(公告)号：EP0295043A2

公开(公告)日：1988-12-14

申请号：EP88305166.6

申请日：1988-06-07

申请人： THE KITASATO INSTITUTE

发明人： Makino, Satoshi ,  Sasaki,Keiko ,  Nakagawa, Masaharu

IPC分类号： A61K39/12

CPC分类号： A61K39/165 ,  A61K39/12 ,  A61K39/20 ,  A61K2039/5254 ,  C12N2760/18434 ,  C12N2760/18734 ,  C12N2770/36234

摘要： A vaccine, which comprises at least one live attenuated plain virus selected from measles, mumps or rubella virus and, as a stabilizing agent, 2.5 to 5 W/V% lactose, 2.5 to 5 W/V% saccharose, 1.8 to 2 W/V% D-sorbitol, about 0.1 W/V% sodium glutamate and 2 to 3 W/V% gelatin hydrolysate having a molecular weight of about 35,000.

摘要翻译： 一种疫苗，其包含选自麻疹，腮腺炎或风疹病毒的至少一种活的减毒平原病毒，作为稳定剂，2.5至5W / V％乳糖，2.5至5W / V％蔗糖，1.8至2W / V％D-山梨糖醇，约0.1W / V％谷氨酸钠和2至3W / V％的明胶水解产物，其分子量约为35,000。

公开(公告)号：EP0013188B1

公开(公告)日：1983-02-23

申请号：EP79400050.5

申请日：1979-01-24

申请人： Merck & Co., Inc.

发明人： Buynak, Eugene Bernard ,  Hilleman, Maurice Ralph

IPC分类号： A61K39/155 ,  C12N7/08

CPC分类号： A61K39/155 ,  A61K39/12 ,  A61K2039/5254 ,  C12N2760/18634 ,  C12N2760/18734

公开(公告)号：EP3393511A1

公开(公告)日：2018-10-31

申请号：EP16880067.0

申请日：2016-12-21

申请人： La Jolla Institute for Allergy and Immunology

发明人： HO, Patrick, H. ,  KOLLA, Ravi

IPC分类号： A61K39/13 ,  A61K39/165 ,  A61K39/20 ,  A61K39/25 ,  A61P35/00

CPC分类号： A61K39/13 ,  A61K39/12 ,  A61K39/165 ,  A61K39/20 ,  A61K39/25 ,  A61K2039/585 ,  C12N7/00 ,  C12N2710/16643 ,  C12N2710/16734 ,  C12N2760/18434 ,  C12N2760/18734 ,  C12N2770/32634 ,  C12N2770/36234 ,  Y02A50/466

摘要： Presented herein are novel methods of treating cancer, which methods result in the expression of peptide epitopes on a cancer. The peptide epitopes are selected to initiate a recall immune response in a subject (e.g., a pre-existing immune response that may have been induced by a vaccination), which immune response is directed toward the cancer. In certain embodiments, the methods herein are used in combination with existing cancer therapies.

公开(公告)号：EP3274447A1

公开(公告)日：2018-01-31

申请号：EP16721253.9

申请日：2016-03-28

申请人： Cadila Healthcare Limited

发明人： GLUECK, Reinhard ,  GIANNINO, Viviana ,  GUPTA, Gaurav

IPC分类号： C12N7/00

CPC分类号： C12N7/00 ,  C12N7/04 ,  C12N2760/18721 ,  C12N2760/18734 ,  C12N2760/18751 ,  C12N2760/18761

摘要： The present invention provides a novel vaccine against mumps composed of highly immunogenic rMuVJL2 (recombinant mumps virus Jeryl Lynn2 based). Further, method to develop said immunogenic composition is described in the present invention. The vaccine according to the present invention is safe, cost effective, highly efficacious and stable and consistent in terms of productivity.

公开(公告)号：EP3053593A1

公开(公告)日：2016-08-10

申请号：EP14850738.7

申请日：2014-10-02

申请人： Nitto Denko Corporation

发明人： KIYOTOH Eiji ,  HORI Mitsuhiko ,  OKUBO Katsuyuki ,  ASARI Daisuke ,  OKAZAKI Arimichi ,  FUKASAKA Masahiro ,  MATSUSHITA Kyohei

IPC分类号： A61K39/02 ,  A61K39/12 ,  A61K39/39 ,  A61P31/04 ,  A61P35/00

CPC分类号： A61K39/39 ,  A61K39/00 ,  A61K39/0011 ,  A61K39/08 ,  A61K39/092 ,  A61K39/12 ,  A61K39/125 ,  A61K39/13 ,  A61K39/145 ,  A61K39/15 ,  A61K39/165 ,  A61K39/205 ,  A61K39/25 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/543 ,  A61K2039/55572 ,  A61K2039/575 ,  C12N2710/16734 ,  C12N2710/20034 ,  C12N2720/12334 ,  C12N2760/18434 ,  C12N2760/18734 ,  C12N2760/20134 ,  C12N2770/24134 ,  C12N2770/32434 ,  C12N2770/32634 ,  C12N2770/36234

摘要： The present invention provides a nasal mucosal vaccine composition which is safe, useful as a preventive or therapeutic agent for infectious diseases or cancers, and capable of inducing systemic immune responses and mucosal immune responses effectively. The present invention provides a nasal mucosal vaccine composition to be administered to a human or animal nasal mucous membrane, the nasal mucosal vaccine composition containing at least one antigen excluding antigens derived from influenza viruses; and as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, or a salt thereof.

摘要翻译： 本发明提供一种鼻粘膜疫苗组合物，其安全，有效地用作感染性疾病或癌症的预防或治疗剂，并且能够有效地诱导全身免疫应答和粘膜免疫应答。 本发明提供了向人或动物鼻粘膜施用的鼻粘膜疫苗组合物，所述鼻粘膜疫苗组合物含有至少一种抗原，其不包括源自流感病毒的抗原; 并且作为佐剂，来自至少一种选自沙雷氏菌属（Salratia），莱克氏菌属（Leclercia），拉氏梭菌（Rahnella），酸性d螨属（Acidicaldus），酸性，螨属（Acidical，，，，，era era era era era era era era，，，，，，，as as as as as，ia ia ia ia ia ia ia ia occus occus occus occus，ia ia ia ia，，，，，，，，，，，，，，，， （Leahibacter），红球菌属（Myocosococcus），梭状芽胞杆菌属（Streptologica），拟青霉属（Lactobacter），泛菌属， 和肠杆菌属或其盐。

公开(公告)号：EP2699266A4

公开(公告)日：2014-12-24

申请号：EP12774253

申请日：2012-04-23

申请人： TUFTS COLLEGE

发明人： KAPLAN DAVID L ,  OMENETTO FIORENZO

IPC分类号： A61K47/42 ,  A61J1/00 ,  A61K35/76 ,  A61K39/00 ,  A61K39/12 ,  A61M5/00 ,  B82Y5/00

CPC分类号： A61K39/20 ,  A61K9/0019 ,  A61K9/06 ,  A61K9/146 ,  A61K9/19 ,  A61K9/5026 ,  A61K9/5063 ,  A61K9/7007 ,  A61K38/00 ,  A61K39/0015 ,  A61K39/02 ,  A61K39/04 ,  A61K39/08 ,  A61K39/092 ,  A61K39/095 ,  A61K39/099 ,  A61K39/12 ,  A61K39/165 ,  A61K47/42 ,  A61K47/46 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/6031 ,  A61K2039/622 ,  A61K2039/64 ,  A61K2039/70 ,  B82Y5/00 ,  C12N2760/18434 ,  C12N2760/18734 ,  C12N2770/36234

摘要： Provided herein are methods and compositions for stabilization of active agents. The active agents are distributed, mixed or embedded in a silk fibroin matrix, thereby retaining the bioactivity of the active agents upon storage and/or transportation. In some embodiments, the storage-stable vaccine-silk compositions are also provided herein.

摘要翻译： 本文提供了用于稳定活性剂的方法和组合物。 活性剂分布，混合或嵌入丝素蛋白基质中，从而保持活性剂在储存和/或运输过程中的生物活性。 在一些实施方案中，本文还提供了储存稳定的疫苗丝组合物。

公开(公告)号：EP2661278A1

公开(公告)日：2013-11-13

申请号：EP12732263.4

申请日：2012-01-04

申请人： Jennerex Inc. ,  Sillajen, Inc.

发明人： KIRN, David ,  BELL, John ,  BREITBACH, Caroline ,  MOON, Anne ,  HWANG, Tae-Ho ,  LEE, Yu Kyoung ,  KIM, Mi-kyung

IPC分类号： A61K39/12

CPC分类号： A61K39/285 ,  A61K35/26 ,  A61K35/76 ,  A61K35/761 ,  A61K35/763 ,  A61K35/768 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/125 ,  A61K39/145 ,  A61K39/165 ,  A61K39/17 ,  A61K39/205 ,  A61K39/235 ,  A61K39/245 ,  A61K39/395 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/55522 ,  C07K16/18 ,  C07K16/30 ,  C07K2317/14 ,  C07K2317/734 ,  C12N7/00 ,  C12N2710/10034 ,  C12N2710/16632 ,  C12N2710/16634 ,  C12N2710/24034 ,  C12N2710/24132 ,  C12N2720/12232 ,  C12N2750/14034 ,  C12N2760/16034 ,  C12N2760/18134 ,  C12N2760/18434 ,  C12N2760/18734 ,  C12N2760/20034 ,  C12N2760/20232 ,  C12N2770/32034 ,  C12N2770/32334 ,  C12N2770/36034 ,  G01N33/574

摘要： The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.

公开(公告)号：EP2471936A3

公开(公告)日：2013-04-24

申请号：EP12161495.2

申请日：2005-11-24

申请人： The Research Foundation for Microbial Diseases of Osaka University ,  National Institute of Biomedical Innovation

发明人： Mori, Yasuko ,  Somboonthum, Pranee ,  Yoshii, Hironori ,  Gomi, Yasuyuki ,  Takahashi, Michiaki ,  Yamanishi, Koichi

IPC分类号： C12N15/869 ,  A61K39/165 ,  A61K39/25 ,  A61K39/295 ,  A61P31/22 ,  A61P37/04 ,  C12N5/00 ,  C12N7/00

CPC分类号： A61K39/25 ,  A61K39/12 ,  A61K39/165 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/70 ,  C12N15/86 ,  C12N2710/16734 ,  C12N2710/16743 ,  C12N2710/16762 ,  C12N2760/18734 ,  C12N2800/204 ,  C12N2800/50 ,  C12N2820/55 ,  Y02A50/39 ,  Y02A50/394

摘要： The problems to be solved by the present invention are to provide: a recombinant varicella-zoster virus; a process for producing the same; a pharmacological composition containing a recombinant varicella-zoster virus; a vector containing a BAC vector sequence in the specific gene of a genomic gene of varicella-zoster virus; cells containing such a vector; a fragment capable of homologous recombination with a genome of varicella-zoster virus; a nucleic acid cassette containing the BAC vector sequence; and a multivalent vaccine. The above problems were solved by developing a process for producing a recombinant varicella-zoster virus, wherein the BAC vector sequence is inserted into a specific virus gene.

公开(公告)号：EP2528622A2

公开(公告)日：2012-12-05

申请号：EP11704349.7

申请日：2011-01-26

申请人： The Regents of the University of Colorado

发明人： HODGES, Robert, S. ,  HOLMES, Kathryn, V. ,  YAN, Zhe ,  HARTSOCK, Wendy, J. ,  QIAN, Zhaohui ,  HIRSCH, Brooke, Elizabeth Bishop

IPC分类号： A61K39/145 ,  A61K39/385

CPC分类号： A61K39/385 ,  A61K39/12 ,  A61K39/145 ,  A61K2039/55505 ,  A61K2039/55566 ,  A61K2039/6081 ,  A61K2039/645 ,  A61K2039/70 ,  C12N2760/16134 ,  C12N2760/18534 ,  C12N2760/18634 ,  C12N2760/18734 ,  C12N2770/20034

摘要： The disclosure relates at least in part to embodiments of compositions and methods including vaccines for protection against multiple serologically distinct strains of influenza virus. This disclosure provides significant advances and addresses important needs in the influenza vaccine field.

公开(公告)号：EP1954308B1

公开(公告)日：2011-09-07

申请号：EP06814694.3

申请日：2006-09-15

申请人： Merial Ltd.

发明人： BELIN-POPUT, Delphine, Magali ,  GENIN, Noel Yves Henri, Jean

IPC分类号： A61K39/155 ,  A61K39/175 ,  A61K39/295

CPC分类号： A61K39/12 ,  A61K9/0019 ,  A61K39/155 ,  A61K39/175 ,  A61K47/183 ,  A61K47/26 ,  A61K2039/5254 ,  A61K2039/552 ,  C12N2710/10334 ,  C12N2750/14334 ,  C12N2760/18434 ,  C12N2760/18734

摘要： The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the present invention relates to stabilizers for freeze-dried live attenuated immunogenic and/or vaccine compositions, which may comprise, inter alia, canine paramyxovirus. The invention further relates to stabilized, freeze-dried live attenuated immunogenic and/or vaccine compositions of, for example, canine paramyxovirus, which may contain these stabilizers. Other aspects of the invention are described in or are obvious from the following disclosure, and are within the ambit of the invention.